Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Surveillance (PMS) on Long-term Use of Tiotropium+Olodaterol Fixed Dose Combination (Tio+Olo FDC) 5µg/5µg in Patients With Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) in Japan

NCT02850978 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02850978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02850978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Surveillance (PMS) on Long-term Use of Tiotropium+Olodaterol Fixed Dose Combination (Tio+Olo FDC) 5µg/5µg in Patients With Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) in Japan
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
August 23, 2016
Completion date
November 30, 2018
Enrollment
1,335 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive